Summary & Overview
HCPCS Level II J1571: Hepatitis B Immune Globulin Injection, 0.5 ml
HCPCS Level II code J1571 denotes a 0.5 ml intramuscular injection of hepatitis B immune globulin (Hepagam B), used for passive immunization against hepatitis B. This code is important nationally for billing and coverage of post-exposure prophylaxis and other clinical indications where immediate antibody-mediated protection is required. Accurate use of J1571 affects provider reimbursement, patient access to prophylactic therapy, and inventory management for specialty biologic products.
Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of national coverage context, common billing considerations, and typical sites of service for administration. The publication also summarizes benchmarking metrics where available, highlights recent policy or coding clarifications that affect billing pathways, and outlines the clinical context in which J1571 is applied.
This resource is intended to inform billing staff, revenue cycle managers, and clinical administrators about the coding purpose of J1571, common operational settings for administration, and the payer landscape relevant to claims adjudication and program planning.
Billing Code Overview
HCPCS Level II code J1571 represents an injection of hepatitis B immune globulin (Hepagam B) administered intramuscularly in a 0.5 ml volume. The service type is an injectable biologic therapy for passive immunization against hepatitis B.
The typical site of service for this injection includes outpatient clinics, physician offices, urgent care centers, and other ambulatory care settings where intramuscular injections are performed. Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric patient with recent known or potential exposure to hepatitis B virus who requires passive immunization with hepatitis B immune globulin (J1571). The patient may present to an outpatient clinic, emergency department, urgent care, or hospital observation unit after a needle-stick, household contact with an infected person, sexual exposure, or perinatal exposure (newborn of a hepatitis B surface antigen–positive mother). The clinical workflow includes verification of exposure risk and timing, review of hepatitis B vaccination history and serologies if available, informed consent for immunoglobulin administration, screening for IgA deficiency and prior severe reactions, preparation of the intramuscular 0.5 mL dose, administration (typically deltoid or anterolateral thigh for infants), and documentation of lot number, expiration date, administration site, and patient response. Post‑administration observation for immediate adverse reactions (usually 15–30 minutes) is performed. Vaccine or vaccine series scheduling and coordination with public health recommendations or infectious disease follow-up occur as indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Standard; no modifier | When no specific modifier applies and routine billing is appropriate |